信隆健康(002105) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥511,351,040.77, a decrease of 12.67% compared to ¥585,539,472.88 in the same period last year[3] - Net profit attributable to shareholders was ¥45,395,423.02, down 23.57% from ¥59,397,700.22 year-on-year[3] - Total operating revenue for Q1 2022 was RMB 511,351,040.77, a decrease of 12.6% compared to RMB 585,539,472.88 in the same period last year[15] - Operating profit for Q1 2022 was RMB 57,840,592.69, compared to RMB 70,429,974.32 in Q1 2021, reflecting a decline of 18.0%[16] - The total comprehensive income attributable to the parent company was CNY 45.47 million, compared to CNY 59.43 million in Q1 2021, reflecting a decrease of 23.5%[20] - The net profit for Q1 2022 was CNY 51.93 million, down 20.38% from CNY 65.25 million in Q1 2021[20] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to ¥15,248,893.03, compared to a negative cash flow of ¥15,971,124.05 in the previous year, marking a 195.48% increase[3] - The net cash flow from operating activities was CNY 15.25 million, a significant improvement from a net outflow of CNY 15.97 million in the same period last year[21] - Cash and cash equivalents at the end of Q1 2022 were RMB 458,910,565.65, slightly down from RMB 459,199,753.69 at the beginning of the year[12] - The cash and cash equivalents at the end of Q1 2022 were CNY 458.91 million, slightly down from CNY 459.20 million at the beginning of the quarter[21] - The cash outflow from investing activities was CNY 15.73 million, a decrease from CNY 17.64 million in Q1 2021[21] - The cash flow from financing activities showed a net inflow of CNY 35.19 thousand, compared to a net outflow of CNY 18.86 million in Q1 2021[21] Assets and Liabilities - Total assets decreased by 5.67% to ¥2,153,063,155.26 from ¥2,282,496,355.80 at the end of the previous year[3] - The company's total assets as of March 31, 2022, were RMB 2,153,063,155.26, down from RMB 2,282,496,355.80 at the beginning of the year, a decrease of 5.6%[15] - Total liabilities decreased to RMB 1,157,427,705.21 from RMB 1,338,849,640.65, representing a reduction of 13.5%[14] Shareholder Equity and Earnings - The company's equity attributable to shareholders increased by 5.33% to ¥898,415,685.89 from ¥852,965,312.46 at the end of the previous year[3] - The company's equity attributable to shareholders increased to RMB 898,415,685.89 from RMB 852,965,312.46, an increase of 5.3%[15] - The basic earnings per share decreased by 23.31% to ¥0.125 from ¥0.163 in the same period last year[3] - The company reported a basic and diluted earnings per share of CNY 0.125, compared to CNY 0.163 in Q1 2021[20] - The weighted average return on equity fell to 5.18%, down 3.51% from 8.69% in the previous year[3] Operating Costs and Subsidies - The company experienced a 13.66% reduction in operating costs, which amounted to ¥402,172,166.09 compared to ¥465,801,927.60 in the previous year[6] - Total operating costs for Q1 2022 were RMB 453,050,530.40, down 12.0% from RMB 514,947,064.30 year-on-year[15] - The company reported a significant increase in government subsidies, totaling ¥660,725.34, up 51.27% from ¥436,777.60[7] Investment Performance - The company’s investment income showed a substantial loss of ¥1,084,423.13, which is a 92.94% increase in losses compared to the previous year[7] - The company reported a net investment loss of RMB 1,084,423.13 in Q1 2022, compared to a loss of RMB 562,047.23 in the previous year[15] Other Information - The company did not report any new product launches or significant market expansion strategies during this quarter[22] - The company received tax refunds amounting to CNY 30.02 million, an increase from CNY 17.83 million in the previous year[20]